Tags

Type your tag names separated by a space and hit enter

HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant.
Curr Res Transl Med. 2019 05; 67(2):51-55.CR

Abstract

HLA-DP mismatched allogeneic hematopoietic stem cell transplantation (allo-HCT) is associated with increased risk of aGVHD and decreased risk of relapse with no effects on overall survival (OS). It has been proposed that CMV-reactivation induces expression of HLA-DP molecules on GVHD target tissues by releasing inflammatory cytokines. We hypothesized that the increased GVHD incidence in HLA-DP mismatched allo-SCTs correlates with recipient CMV serostatus or CMV reactivation. In addition, CMV reactivation is associated with increased risk of GVHD with an unknown mechanism. Here, we analyzed the association between HLA-DPB1 and CMV reactivation on cumulative incidence of aGVHD and relapse as well as OS in 613 patients with AML and MDS who underwent matched related or unrelated allo-HCT at MD Anderson Cancer Center from 2005 to 2011. In multivariable analysis, HLA-DPB1 mismatching was associated with increased risk of aGVHD (hazard ratio (HR): 1.53, P < 0.001) independent of CMV serostatus and CMV reactivation. Additionally, HLA-DPB1 mismatching was associated with decreased risk of relapse and no effect on OS. CMV reactivation increased risks of aGVHD (HR: 5.82, P < 0.001) independent of HLA-DP mismatching with no effect on relapse or OS. In conclusion, our data suggests that HLA-DPB1 mismatching and CMV reactivation increase risk of aGVHD independently.

Authors+Show Affiliations

Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA. Electronic address: arminghobadi@wustl.edu.The University of Texas MD Anderson Cancer Center, Department of Biostatistics, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Infectious Diseases, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.The University of Texas MD Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy, Houston, TX, USA.

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

30683577

Citation

Ghobadi, Armin, et al. "HLA-DP Mismatch and CMV Reactivation Increase Risk of aGVHD Independently in Recipients of Allogeneic Stem Cell Transplant." Current Research in Translational Medicine, vol. 67, no. 2, 2019, pp. 51-55.
Ghobadi A, Milton DR, Gowda L, et al. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019;67(2):51-55.
Ghobadi, A., Milton, D. R., Gowda, L., Rondon, G., Chemaly, R. F., Hamdi, A., Alousi, A., Afrough, A., Oran, B., Ciurea, S., Kebriaei, P., Popat, U. R., Qazilbash, M. H., Shpall, E. J., Champlin, R. E., & Bashir, Q. (2019). HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Current Research in Translational Medicine, 67(2), 51-55. https://doi.org/10.1016/j.retram.2019.01.001
Ghobadi A, et al. HLA-DP Mismatch and CMV Reactivation Increase Risk of aGVHD Independently in Recipients of Allogeneic Stem Cell Transplant. Curr Res Transl Med. 2019;67(2):51-55. PubMed PMID: 30683577.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. AU - Ghobadi,Armin, AU - Milton,Denái R, AU - Gowda,Lohith, AU - Rondon,Gabriela, AU - Chemaly,Roy F, AU - Hamdi,Amir, AU - Alousi,Amin, AU - Afrough,Aimaz, AU - Oran,Betul, AU - Ciurea,Stefan, AU - Kebriaei,Partow, AU - Popat,Uday R, AU - Qazilbash,Muzaffar H, AU - Shpall,Elizabeth J, AU - Champlin,Richard E, AU - Bashir,Qaiser, Y1 - 2019/01/23/ PY - 2018/11/06/received PY - 2019/01/10/revised PY - 2019/01/15/accepted PY - 2019/1/27/pubmed PY - 2020/8/29/medline PY - 2019/1/27/entrez KW - Allogeneic hematopoietic stem cell transplantation KW - CMV KW - HLA-DP SP - 51 EP - 55 JF - Current research in translational medicine JO - Curr Res Transl Med VL - 67 IS - 2 N2 - HLA-DP mismatched allogeneic hematopoietic stem cell transplantation (allo-HCT) is associated with increased risk of aGVHD and decreased risk of relapse with no effects on overall survival (OS). It has been proposed that CMV-reactivation induces expression of HLA-DP molecules on GVHD target tissues by releasing inflammatory cytokines. We hypothesized that the increased GVHD incidence in HLA-DP mismatched allo-SCTs correlates with recipient CMV serostatus or CMV reactivation. In addition, CMV reactivation is associated with increased risk of GVHD with an unknown mechanism. Here, we analyzed the association between HLA-DPB1 and CMV reactivation on cumulative incidence of aGVHD and relapse as well as OS in 613 patients with AML and MDS who underwent matched related or unrelated allo-HCT at MD Anderson Cancer Center from 2005 to 2011. In multivariable analysis, HLA-DPB1 mismatching was associated with increased risk of aGVHD (hazard ratio (HR): 1.53, P < 0.001) independent of CMV serostatus and CMV reactivation. Additionally, HLA-DPB1 mismatching was associated with decreased risk of relapse and no effect on OS. CMV reactivation increased risks of aGVHD (HR: 5.82, P < 0.001) independent of HLA-DP mismatching with no effect on relapse or OS. In conclusion, our data suggests that HLA-DPB1 mismatching and CMV reactivation increase risk of aGVHD independently. SN - 2452-3186 UR - https://www.unboundmedicine.com/medline/citation/30683577/HLA_DP_mismatch_and_CMV_reactivation_increase_risk_of_aGVHD_independently_in_recipients_of_allogeneic_stem_cell_transplant_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2452-3186(19)30001-7 DB - PRIME DP - Unbound Medicine ER -